Banka BioLoo Limited
National Stock Exchange of IndiaTotal Valuation
Banka BioLoo Limited carries a market capitalization of 1.02B, placing it among publicly traded companies globally. Its enterprise value stands at 613.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.02B |
| Enterprise Value | 613.96M |
Valuation Ratios
Banka BioLoo Limited trades at a trailing price-to-earnings ratio of 121.24. The price-to-sales ratio is 0.80, and the price-to-book ratio stands at 4.17.
| PE Ratio | 121.24 |
| PS Ratio | 0.80 |
| PB Ratio | 4.17 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Banka BioLoo Limited trades at an EV/EBITDA multiple of 25.96 and an EV/FCF ratio of 89.77. The EV/Sales ratio of 1.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.96 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.08 |
| EV / EBITDA | 25.96 |
| EV / EBIT | 25.96 |
| EV / FCF | 89.77 |
Financial Position
Banka BioLoo Limited maintains a current ratio of 1.58, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 95.84, indicating elevated leverage, while an interest coverage ratio of 0.65 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.58 |
| Quick Ratio | 0.66 |
| Debt / Equity | 95.84 |
| Debt / EBITDA | 17.25 |
| Interest Coverage | 0.65 |
Financial Efficiency
| Return on Equity (ROE) | 2.30 |
| Return on Assets (ROA) | 0.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.35 |
Taxes
| Income Tax | -6.58M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Banka BioLoo Limited's stock has gained approximately 30.15432% over the past 52 weeks. The 50-day moving average sits at 86.99, while the 200-day moving average is 73.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | 30.15432% |
| 50-Day Moving Average | 86.99 |
| 200-Day Moving Average | 73.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Banka BioLoo Limited generated 570.93M in revenue and converted that into 3.76M in net income, yielding earnings per share of 0.36. EBITDA reached 23.65M, while operating income came in at 23.65M.
| Revenue | 570.93M |
| Gross Profit | 430.83M |
| Operating Income | 23.65M |
| Pretax Income | -2.65M |
| Net Income | 3.76M |
| EBITDA | 23.65M |
| EBIT | 23.65M |
| Earnings Per Share (EPS) | 0.36 |
Balance Sheet
Banka BioLoo Limited holds 279.78M in cash and equivalents against 408.03M in total debt, resulting in a net debt position of 291.37M. Total book value stands at 109.22M, with working capital of 248.05M providing operational flexibility.
| Cash & Cash Equivalents | 279.78M |
| Total Debt | 408.03M |
| Net Debt | 291.37M |
| Equity (Book Value) | 109.22M |
| Book Value Per Share | 10.06 |
| Working Capital | 248.05M |
Margins
Banka BioLoo Limited operates with a gross margin of 75.46, reflecting its pricing power and cost economics. The operating margin of 4.14 and net profit margin of 0.66 provide insight into operational efficiency.
| Gross Margin | 75.46 |
| Operating Margin | 4.14 |
| Pretax Margin | -0.46 |
| Profit Margin | 0.66 |
| EBITDA Margin | 4.14 |
Stock Splits
Banka BioLoo Limited's most recent stock split took place on September 8, 2020 with a 2:5 split ratio.
| Last Split Date | 9/8/2020 |
| Split Ratio | 2:5 |
Scores
Banka BioLoo Limited posts an Altman Z-Score of 1.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.41 |